Providing You with the most Innovative & Advanced Products
We're dedicated to your health!
What We Do
Commitment to Innovation
Drug Development and Testing
Drug Development and Testing
Our company understands the technology and medicine in the health care industry is consistently progressing. Our team of experienced professionals stays current about the latest drug trends.
Drug Development and Testing
Drug Development and Testing
Drug Development and Testing
Our team is constantly keeping up with medical trends and technology and strive to find better ways to improve the health of our patients in an ever-changing industry.
Pharmaceutical Manufacturing
Drug Development and Testing
Pharmaceutical Manufacturing
Other drug developers will work with us to support clinical trials. We maintain the highest level of safety when it comes to testing, manufacturing, and transferring of products.
Meet Our Newest Product
H-D1
Meet our newest product, the H-D1, an innovative targeted treatment drug integrating the DNA-binding technology and FRET mechanism with in
1. Precisely track and evaluate the curative effect
2. Highly increases the effectiveness of Cervical cancer Treatment
3. Reduces toxins and side-effects on patients
Validations/Experiments
The Effectiveness of DNA-DOX Drug through comparison
As shown in Figure (a), the survival rate of HeLa cells in PBS (buffer, pH = 7.4) and H1 hairpin was close to 100%, indicating that the nano material had little damage to HeLa cells. However, the cell survival rate was greatly reduced in the DOX drug, indicating that DOX can kill cancer cells well. Subsequently, the survival rate is further reduced in the H-D1 group. The above results showed that H-D1 drug could effectively kill HeLa cells, and H-D1 could stay in the cell interior well. But DOX alone could not kill cells efficiently because DOX alone could not stay inside HeLa.
Effectiveness of DNA-DOX in different concentrations
As shown in Figure (b), the cell survival rate slowly decreased with the increase of DNA-DOX drug concentration. At a DNA-DOX concentration of 30μm, the cell survival rate was about 37%, effectively killing most HeLa cells.
DNA-FAM detection of miRNA(0-10μM)
In Figure (a), the fluorescence response of DNA nano-materials to miRNA-21 was measured, as shown in Figure 1. In Figure (a), with the addition of miRNA-21, FAM characteristic peak appears at 520nm, and the fluorescence increases gradually with the addition of miRNA-21.
DNA-FAM-DOX detection of miRNA(0-10μM)
Next, in Figure (b), characteristic peaks of FAM (520nm) and DOX (590nm) appeared in H-D1 with the addition of miRNA-21. The above results indicate that H1 and H-D1 nano-materials can achieve a good response to miRNA-21 and release cancer treatment drug DOX.
The Targeted Diagnosis of DNA-DOX(H-D1)
In HUVEC (Human Umbilical Vein Endothelial Cells) and HeLa (cervical cancer cells), the therapeutic effect of H-D1 was analyzed by fluorescence imaging technology. As shown in Figure, it was found that H-D1 only showed green and red light in HeLa cells, but did not show obvious fluorescence in HUVEC cells. Because HUVEC is a normal cell, the expression of miRNA-21 is low in HUVEC cells. Therefore, FAM and DOX fluorescence could not be emitted by binding to H-D1 and unwinding the helix in HUVEC. On the other hand, in HeLa cells, miRNA-21 is highly expressed, which can uncoil H-D1 by pairing with DNA bases, releasing FAM fluorescence and therapeutic drug DOX. The above results fully indicate that H-D1 can achieve precise targeted diagnosis and treatment of cancer cells.
experimentation moments
